Navigation Links
Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30, 2013, on Tuesday, November 12, 2013 prior to market open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36014873.

The following day, Orexigen management will present a company overview at the Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation is scheduled for Wednesday, November 13th at 9:30 a.m. Mountain Time.  

The webcasts of the live and subsequently archived conference call and conference presentation can be accessed on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following each event.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
3. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
4. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
5. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
10. Orexigen Therapeutics to Present at Upcoming Investor Conferences
11. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/4/2016)... 2016 For hospitals considering enrollment in the ... in the program, the Health Resources and Services Administration,s ... , Mega-Guidance , could have significant impact on plans ... September 2016. Essential Insights , Daniel ... summarizes the Mega-Guidance,s key proposed changes, including a new ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, ... announced it has entered into a settlement agreement ... (SEC) fully resolving the SEC,s investigation into possible ... Under the terms of the settlement agreement, SciClone ... million, including disgorgement, pre-judgment interest and a penalty.  ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
Breaking Medicine News(10 mins):